The lack of effectiveness of these antibodies is likely attributed to the fact that they are designed to block the activity of the epidermal growth factor receptor (EGFR), which is overexpressed in some cancer cells, a characteristic not observed in TNBC breast cancer. This evidence concerns the gene EGFR and cancer.